AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist

<p>BOSTON, Feb.</p>
<p>The post <a href="https://forextv.com/top-news/aveo-oncology-announces-publication-of-long-term-survival-in-patients-with-relapsed-refractory-advanced-renal-cell-carcinoma-treated-with-tivozanib-analysis-of-the-phase-iii-tivo-3-trial-in-the-oncol/">AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>